Assessing the performance of a continuous infusion for potassium supplementation in the critically ill 
SUMMARy
Hypokalaemia is a common problem in critically ill patients, which if untreated, can result in dysrhythmia or another adverse outcome. we assessed the safety and efficacy of a continuous infusion of potassium chloride versus an existing intermittent infusion regimen. In this open-label randomised parallel-arm activecontrolled pilot study, critically ill adults with plasma potassium concentration between 2.5 and 3.8 mmol/l were randomised to receive either a continuous infusion or intermittent infusions of potassium chloride for establishment and maintenance of normokalaemia. The primary outcome was the mean difference in plasma potassium concentration over time between the two study arms as assessed by a linear mixed-effects model. Although a statistically significant difference was observed (0.22 mmol/l; 95% confidence interval 0.17, 0.27; P <0.0001), this did not reach the pre-determined level indicative of a treatment effect (0.5 mmol/l). The continuous group demonstrated less variance in (mean) plasma potassium as reflected in narrower confidence intervals in a prediction-by-time model. The incidence rate ratio of dysrhythmia, assessed by a mixed-effects Poisson model, was similar in each group (0.62; 95% confidence interval 0.32, 1.21; P=0. 16) . we recorded no adverse events directly attributable to infusion of potassium chloride in either study arm. Although titrated continuous infusion did not demonstrate a clinically important difference by comparison with intermittent infusions for the maintenance of normokalaemia, there was more consistent control of plasma potassium with no observed complications or adverse events. Therefore, this trial showed an acceptable efficacy and safety profile for the continuous infusion regimen, suggesting scope for further study.
significant difference in plasma potassium increment versus patients with normal renal function.
Although a computer algorithm-driven administration protocol to maintain normokalaemia has been reported previously in an animal model 13 , no human trial had studied a continuous potassium chloride infusion in the critical care environment. The current investigating unit has successfully implemented a protocol (see Appendix 1 available in the website version) for the safe administration of a continuous potassium infusion and has conducted this trial to assess the efficacy and safety of the administration protocol.
METHODS

Study design
This open-label, randomised, parallel-arm, active control trial was set in a tertiary universityaffiliated intensive care unit (ICU), comparing continuous versus intermittent (active control) infusions of potassium chloride for the maintenance of normokalaemia. The principal study aims were to assess the safety and clinical efficacy of the two infusion models by comparing both the mean difference in plasma potassium concentration over time and the incidence of prospectively defined adverse events between treatment groups.
The local institutional Human Research Ethics Committee reviewed the proposed protocol (application number: 2007185) and waived the need for informed consent. The study was registered with ClinicalTrials.gov as NCT00718068.
Patients
we screened all patients admitted to the ICU from September 2008 to September 2009 for suitability. The principal inclusion criterion was a plasma potassium concentration of greater than 2.5 and less than 3.8 mmol/l. we chose the lower value to ensure that patients would not be unnecessarily exposed to the risks of hypokalaemia and because the continuous infusion model was principally devised for maintenance of normal plasma concentration rather than as a replacement method for established severe hypokalaemia. Other inclusion criteria were the presence of an invasive arterial line to facilitate blood sampling, a central venous catheter for administration of study drug and a serum magnesium level within the normal range (i.e. 0.7 to 1.0 mmol/l) prior to enrolment.
The main exclusion and withdrawal criterion was renal dysfunction based on the Acute Dialysis Quality Initiative's criteria for 'failure' 14 . Specifically, we excluded patients with a serum creatinine concentration greater than 180 µmol/l due to the need to treat hypokalaemia urgently which precluded formally measuring creatinine clearance. This level was well within the range of measured creatinine concentrations of patients safely managed by previous investigators 7, 9, 10 . Treating physicians on the investigating unit had the discretion to decline patients for enrolment or withdraw patients at any point.
Study protocol
Simple randomisation was conducted by a computer-generated random numbers table, with group allocation concealed in opaque envelopes which were opened sequentially. Randomisation was distributed in a 1:1 ratio.
The intervention was a continuous infusion of sterile potassium chloride (Sterile Potassium Chloride Concentrate, Pfizer, Bentley, WA) preprepared as a concentration of 1 mmol/ml, delivered by syringe driver, commencing at 10 ml/hour (i.e. 10 mmol/hour).The control group received intermittent infusions of sterile potassium chloride prepared as 20 mmol in 100 ml of 0.9% sodium chloride (0.2 mmol/ml) delivered by volumetric pump over 60 minutes. This was the standard supplementation method on the investigating unit prior to the current study.
Arterial blood samples were obtained every two hours where possible, as required during the study period for plasma potassium measurement. Physicians or senior nurses adjusted the infusion rate for intervention group patients or administered further infusions to control group patients, as necessary, aiming to maintain normokalaemia (3.5 to 4.9 mmol/l). Figure 1 provides a graphical representation of the protocol flow-sheet.
Due to the differences in study drug preparation and delivery as detailed above, blinding was not possible. However the principal investigator was not directly involved in patient management and treating physicians on the investigating unit had full discretion in all other aspects of care.
Patients completed involvement in the study at time of discharge, death or removal of arterial line or central venous catheter. They were withdrawn from participation on development of the renal dysfunction exclusion criteria, but their data was still included in the pooled analysis. The maximum duration of participation was limited to seven days to prevent long-term ICU patients contributing excessive numbers of data-points and potentially skewing results. 
Data collection
Demographic and baseline data were collected prior to randomisation. These included diagnosis, Acute Physiology and Chronic Health Evaluation II score, heart rate, mean blood pressure, history of dysrhythmia, hourly urine output and serum magnesium, urea and creatinine concentrations.
All potassium measurements used in this study were plasma concentrations assayed with a E772 K-electrode (Radiometer Medical, Mount waverley, Vic.) ion-selective electrode installed in a ABL725 point-of-care analyser (Radiometer Pacific, Mount waverley, Vic.) located within the investigating unit. The manufacturer-determined normal range for plasma potassium concentration for this electrode was 3.5 to 4.9 mmol/l; hence the ideal range used in this study. A 0.5 mmol/l margin outside this range was considered as being within acceptable safety limits. Thus any value less than 3.0 mmol/l or greater than 5.4 mmol/l was considered an 'adverse event'. we chose to use the point-of-care analyser due to the practical limitations of performing assays in the hospital pathology laboratory which is remote from the investigating unit and could not reliably provide immediate, on-demand processing. The potential delays in obtaining results would incur unacceptable risk for study patients receiving continuous infusions of potassium.
All study subjects had continuous electrocardiography and invasive arterial blood pressure monitoring. Dysrhythmia was defined as new-onset atrial fibrillation/flutter, supraventricular tachycardia, non-sustained ventricular tachycardia (i.e. more than 10 complexes), sustained ventricular tachycardia requiring chemical or electrical cardioversion, ventricular fibrillation or pulseless electrical activity. Verification of dysrhythmias was performed by the principal investigator retrospectively reviewing data automatically captured by the investigating unit centralised monitoring system while blinded to patient group allocation.
Statistical analysis
The primary outcome was the difference in plasma potassium levels (over patient-time-in-study) between patients enrolled in the intervention and control arms. Secondary outcomes included the amount of potassium chloride administered, incidence of plasma potassium concentration outside the normal range and incidence of dysrhythmias or other adverse events (for example, cardiac arrest). we considered a 0.50 mmol/l difference in mean potassium concentration as indicative of treatment effect between the two groups based on preliminary work by Kruse et al 7, 10 . Based on pilot data (mean plasma potassium 3.5(0.5) mmol/l on admission to ICU), with an expected conservative increment of 0.25 mmol/l from a continuous regimen and a range of follow-up measurements from 1 to 5 (correlation of the repeated measures of 0.3 to 0.5, 90% power), sample sizes per arm of 30 to 85 patients were calculated. we anticipated enrolling up to 140 patients over a 12 month period. This timeframe was chosen to limit the material and human resource impact on the investigating unit. The primary outcome was analysed using a linear mixedeffects model (unstructured covariance), adjusting for baseline potassium and a time effect 15 . Model specification was checked using residual analysis and comparison of observed and predicted plasma potassium values over time: intra-class correlation was also estimated.
Departures from the normal range of plasma potassium concentration and incidence of dysrhythmias were tabulated as a count variable and analysed by a mixed effects Poisson model, adjusted for exposure as the trial length (loghours) and expressed as an incidence rate ratio (IRR) 16 . Group differences between continuous and categorical variables were analysed by t-test and Fisher's exact test respectively. Stata™ statistical software (V11.2, 2011; College Station, Texas, USA) was used.
RESULTS
Over a 12 month period, commencing September 2008, 185 patients were screened, of whom 139 were enrolled, with even distribution between the two study arms (i.e. 71 patients to the continuous infusion group and 68 patients to the intermittent infusion group). All 139 patients completed the study and contributed data for statistical analysis and modelling (Figure 2) . Table 1 shows pertinent baseline data by group which were well matched between the study arms. Plasma potassium concentration at enrolment was equally matched. There was a statistically significant difference in gender balance between the two groups but we found no plausible explanation for this. 
Primary outcome
The time course of plasma potassium over patient-time-in-study, by group, is seen in Figure  3 12) ; that is, no differential in plasma potassium over time was evident between the groups. The model was well specified with an intra-class correlation of 0.12 and there was good agreement between groups and predicted potassium over time (Figure 4 ).
Secondary outcomes
Patients receiving the continuous infusion accumulated a total of 2618 hours in study versus a total of 2320 hours in the intermittent group. The mean duration of study period per patient was similar between the two study arms with only 6.23 more hours for the continuous versus intermittent group (95% CI -17.01, 29.5; P=0.60). During the study, a total of 2488 plasma potassium concentration measurements were performed, of which 1456 were in the continuous arm and 1014 in intermittent patients. The mean total amount of potassium chloride administered per patient over the study period was 307.6 (238.1) mmol to the continuous infusion and 149.1 (129.1) mmol to the intermittent infusion arm resulting in a statistically significant difference of 158.5 mmol (95% CI 195.2, 264.9, P <0.0001). Emergency surgical 10 11
Elective surgical 9 3
Group mean values with standard deviation in parentheses (except where indicated). * Fisher's exact test across diagnostic categories between the study groups. There were 44 potassium values greater than 4.9 mmol/l in 25 patients: five patients in the intermittent arm (six instances) and 20 patients in the continuous arm (38 instances) and 116 potassium values less than 3.5 mmol/l in 49 patients: 28 patients in the intermittent arm (77 instances) and 21 patients in the continuous arm (39 instances). Of those potassium levels >4.9 mmol/l, four exceeded the predetermined 'adverse event' level for hyperkalaemia (>5.4 mmol/l); being 5.5, 5.5, 5.9 and 6.9 mmol/l respectively, recorded in separate patients in the intermittent group. None of these were associated with dysrhythmia or other undesirable sequelae. The latter two values were potentially invalid recordings as preceding and succeeding measures were within the normal range. There were 14 potassium levels <3.0 in 7 patients: five patients in the intermittent arm (10 instances) and two patients in the continuous arm (four instances). Again, none of these were linked to any detectable adverse clinical event. The incidence rate ratio for dysrhythmias (continuous versus intermittent) was 0.62, 95% CI 0.32, 1.21; P=0.16; with a significant time (0.57, 95% CI 0.48, 0.69; P <0.0001) effect. Dysrhythmias were more frequent with increasing baseline heart rate (IRR 1.03, 95% CI 1.01, 1.05; P <0.001). No episode of ventricular fibrillation, sustained ventricular tachycardia or pulseless electrical activity occurred in any patient during the trial period, and none of the other dysrhythmias in any patient resulted in haemodynamic compromise.
Overall, we observed no adverse events directly attributable to administration of the potassium chloride infusions. No patient died while receiving the study drug and the overall mortality at ICU discharge was four of 71 patients in the intervention group versus nine of the 68 control patients (5.6% and 13.2%, P=0.12). All of these deaths were anticipated as a result of palliation or cessation of active therapy.
DISCUSSION
This trial has shown that a continuous infusion of potassium maintained a slightly higher plasma level over time than did an intermittent infusion regimen, possibly due to the disparity in mean potassium dose and sampling frequency between the two groups. While significant in statistical terms, the 0.22 mmol/l difference observed was not clinically important and fell short of the 0.50 mmol/l difference required to determine a 'positive' treatment effect. However, the continuous infusion, as might be expected in pharmacokinetic terms, did provide more consistent maintenance of plasma potassium concentration over time versus the intermittent infusions, both in the observed and predicted models as shown in Figures 3 and 4 respectively. Of note, 'adverse event' hyperkalaemic values were only recorded in intermittent group patients and there were fewer instances of hypokalaemia in the continuous group. This, and the absence of dysrhythmia or other adverse events, shows in pragmatic terms a reasonable safety profile for the continuous infusion protocol.
It might reasonably be expected that the much larger cumulative dose delivered to the continuous arm (approximately double the intermittent infusion dose) would have resulted in instances of hyperkalaemia. That the opposite was shown suggests that the vigilance of monitoring and senior clinician supervision of study subjects were sufficient to mitigate this potential concern. It is also plausible that the continuous nature of the infusion promoted sequestration and excretion mechanisms in these patients resulting in more efficient autoregulation versus the sporadic nature of potassium infusions in the intermittent regimen 17, 18 . As noted previously, hypokalaemia is a common morbidity experienced by critically unwell patients [1] [2] [3] [4] [5] [6] . Continuous infusions have been used in previous studies but without the degree of focus of this trial. In 1994, Singhi et al reported a case series of 20 paediatric patients with hypokalaemia and electrocardiographic abnormalities 19 . They administered a continuous infusion at 0.25 mmol/ kg/hour until the electrocardiogram normalised. A mean rise of 0.75 mmol/l was recorded and no adverse events resulted. Another small case series reported successful treatment of muscle weakness due to periodic paralysis with a high rate infusion of up to 20 mmol/hour 20 . This seemed to be well tolerated although one patient experienced a rebound hyperkalaemia (5.8 mmol/l). Both sets of investigators ceased potassium administration once treatment success was achieved, so these series reflect more the acute rather than maintenance therapy.
The most recent and relevant investigation was published in 2008 21 . He, wang, Liu and colleagues compared two infusions, 1.2 mmol/ml in the therapy group and 0.2 mmol/ml in the control group, which closely reflect the formulations used in this trial. However, in contrast to our protocol they delivered both concentrations by continuous infusion rather than comparing continuous with intermittent administration. They also enrolled patients with creatinine clearance as low as 30 ml/minute and observed no associated adverse event or instances of hyperkalaemia.
As with any study, our trial has several limitations. First, it was a single-centre study. Second, we relied on the discretion of senior experienced clinicians to titrate the rate and number of potassium infusions rather than a protocolised algorithm, as the safety of continuous potassium infusion administration was a primary concern. The one hour period after completion of the infusion in the intermittent arm is at odds with the continuous nature of the intervention arm, whose patients would still be receiving potassium at time of sampling. On balance it is unlikely that this would have a marked effect on measured level since sampling was performed remote to the administration route and cellular sequestration of administered potassium is rapid and highly efficient 3, 7 . Plasma potassium concentration is dependent on many factors and poorly representative of total body potassium 3 , so devising such a protocol ahead of the trial was deemed impractical, especially since this was a pilot investigation for the continuous infusion. However, we acknowledge the apparent greater vigilance to the intervention group may have introduced a Hawthorne effect and influenced results. Measurement of urinary potassium excretion may have helped our understanding of the physiological response to each potassium infusion method, but this was not performed. Similarly we performed no simultaneous plasma potassium assays with the hospital chemical pathology service's automated analyser which may have been useful to ensure validity and consistency of measurements by the Radiometer ABL725, although the latter machine is routinely maintained and calibrated to manufacturer specifications and is a nationally accredited Category S (Specialised) laboratory under Australian Standard 4633 (ISO 15189). Last, the lack of standardisation in dosage between patients both within each group and between the two groups may have introduced undesirable variation in treatment and the potential for bias, especially in the context of an unblinded investigation. while we would have preferred to double-blind this study, safety and logistic requirements mandated otherwise.
Rather than act as a panacea for potassium delivery in the intensive care unit, we view the continuous infusion as an adjunct to existing supplementation or maintenance methods, especially in patients unable to receive or tolerate enteral potassium supplements. Instead of adding fixed amounts of potassium to maintenance fluids, we can tailor administration to meet patient requirements. The amount administered per day can be adjusted minutely while still allowing a large dosing range. During our trial we observed some patients requiring in excess of 300 mmol per day to maintain normokalaemia, which is difficult to achieve with more conventional supplementation methods. The low infusion rates required can also mitigate risks of fluid overload by minimising daily volume administration. This may prove useful since the intensive care community has observed adverse outcomes associated with excessive positive fluid balance in some patient categories [22] [23] [24] . There is much scope for further study based on this pilot investigation. A 'sliding scale' analogous to the Bath protocol would facilitate use of continuous infusions by critical care units previously unfamiliar with their use 25 . Evaluation of computer-aided infusion-rate titration is already planned at another centre 26 . Thereafter, a multicentre study would be indicated to determine wider scale utility and feasibility.
CONCLUSIONS
In this trial, a continuous potassium chloride infusion did not achieve the predefined 0.50 mmol/l difference in mean plasma potassium concentration indicative of a treatment effect over time. However, the consistency of plasma potassium level maintenance, lesser incidence of hypokalaemia by comparison to control patients, and absence of dysrhythmia or other adverse event establish its safety profile and utility for further study.
